Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone Ophthalmic Insert Clear all
Terminated Phase 4 Interventional Results available

Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery

NCT04200651
View directory record Official record
Conditions
Glaucoma, Cataract
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The New York Eye Surgery Center
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

NCT04413279
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
LipiFlow Thermal Pulsation, Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Procedure · Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

ACCURATE Study for Subjects With Dry Eyes

NCT04237012
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Dextenza 0.4Mg Intracanalicular Insert, Over the counter Artificial tears
Drug · Other
Lead sponsor
The Eye Centers of Racine and Kenosha
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses

NCT04479748
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Prism Vision Group
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Vineland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 28, 2026, 12:24 PM EDT
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 28, 2026, 12:24 PM EDT
Recruiting Phase 4 Interventional

Dextenza in the Post-op Management of Vitreoretinal Surgeries

NCT04371445
View directory record Official record
Conditions
Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pharmacokinetics of Aqueous Dexamethasone

NCT04667507
View directory record Official record
Conditions
Pharmacokinetics, Aqueous Dexamethasone, Inflammatory Cytokine Response
Interventions
Dexamethasone Ophthalmic implant
Drug
Lead sponsor
Frank A. Bucci, Jr., M.D.
Other
Eligibility
55 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 28, 2026, 12:24 PM EDT
Not listed Phase 4 Interventional

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

NCT04501367
View directory record Official record
Conditions
Vitrectomy, Macular Pucker, Retinal Edema
Interventions
Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%
Drug
Lead sponsor
Kovach Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Elmhurst, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

NCT04708821
View directory record Official record
Conditions
Bilateral Conjunctivitis (Disorder)
Interventions
Dexamethasone ophthalmic insert 0.4Mg, 0.2% loteprednol etabonate ophthalmic suspension, olopatadine hydrochloride ophthalmic solution 0.7%
Drug
Lead sponsor
Clinical Research Center of Florida
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

NCT05023304
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.

NCT05372315
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Iworks Laser and Vision Center
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 28, 2026, 12:24 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

NCT06235567
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 12:24 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye

NCT04498468
View directory record Official record
Conditions
Dry Eye
Interventions
Sustained Release Dexamethasone, 0.4 mg, E-Caprolactone-L-Lactide copolymer (PCL) punctal plug
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 28, 2026, 12:24 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery

NCT04281862
View directory record Official record
Conditions
Refractive Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Results available

Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study

NCT04168112
View directory record Official record
Conditions
Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain
Interventions
Dextenza, Prednisolone Acetate
Drug
Lead sponsor
Sight Medical Doctors PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Babylon, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

NCT05143281
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone 0.4 MG [Dextenza]
Drug
Lead sponsor
Grene Vision Group
Other
Eligibility
65 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 28, 2026, 12:24 PM EDT
Terminated No phase listed Observational

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

NCT02688309
View directory record Official record
Conditions
Macular Edema, Fibrosis of the Retina
Interventions
Ozurdex, Surgery, Anterior Chamber (AC) Tap
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 28, 2026, 12:24 PM EDT
Terminated Phase 4 Interventional

Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

NCT04687800
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4mg intracanalicular Insert, Durezol 0.05% Ophthalmic Emulsion
Drug
Lead sponsor
Cathleen McCabe MD
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 28, 2026, 12:24 PM EDT
Not listed Phase 4 Interventional

Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.

NCT04592081
View directory record Official record
Conditions
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Kerry Assil, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

NCT04050865
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone, 0.4mg, Placebo plug with no drug
Drug · Device
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Colorado Springs, Colorado • Louisville, Kentucky • Raynham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 28, 2026, 12:24 PM EDT
Terminated Phase 4 Interventional

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

NCT04464629
View directory record Official record
Conditions
Retinal Detachment
Interventions
Dextenza, Prednisolone Acetate
Drug
Lead sponsor
Midwest Eye Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 28, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 28, 2026, 12:24 PM EDT